Related Experiment Video
Updated: Dec 5, 2025
Surface-enhanced Resonance Raman Scattering Nanoprobe Ratiometry for Detecting Microscopic Ovarian Cancer via Folate Receptor Targeting
Published on: March 25, 2019
Nanoparticles in precision medicine for ovarian cancer: From chemotherapy to immunotherapy
1Gynecology and Obstetrics Department, Peking University Third Hospital, Beijing 100191, PR China.
Abstract:
Ovarian cancer is the most common cause of death among gynecological malignancies globally. Ovarian cancer treatment integrates debulking surgery and systemic therapy. Genomic and proteomic analyses have shown that ovarian cancer is heterogeneous with unique molecular characteristics that may facilitate the development of systemic targeted chemotherapeutic and immunotherapeutic precision medicines. However, despite their advantages, these therapies have some limitations. Chemotherapy has drawbacks such as drug resistance and high toxicity due to nonspecific tumor targeting; the targeted versions have limited utility and off-target side effects. Immunotherapy has a low response rate due to the intrinsically immunosuppressive tumor microenvironment in ovarian cancer. Nanotechnology-based drug delivery systems have the potential to overcome such limitations. Various nanoparticles have been developed for controlled drug delivery to ovarian cancer. In this review, we summarize the application of nanotechnology in ovarian cancer systemic therapy including nanoformulations in the market and in clinical trials, as well as the recent nanoparticle research therapeutic strategies. The potential and challenges of nanoparticles in ovarian cancer treatment are also discussed.
Insights
Nanotechnology offers promising solutions for ovarian cancer systemic therapy, overcoming limitations of chemotherapy and immunotherapy. This review explores nanoparticle applications, nanoformulations, and future challenges in treating this gynecological malignancy.
Area of Science:
- Oncology
- Biomedical Engineering
- Nanomedicine
Background:
- Ovarian cancer is a leading cause of death among gynecological malignancies.
- Current treatments like chemotherapy and immunotherapy face challenges including drug resistance, toxicity, and low response rates.
- Tumor microenvironment in ovarian cancer is often immunosuppressive, limiting immunotherapy efficacy.
Purpose of the Study:
- To review the application of nanotechnology in ovarian cancer systemic therapy.
- To discuss nanoformulations in the market and clinical trials.
- To explore recent nanoparticle research and therapeutic strategies for ovarian cancer.
Main Methods:
- Literature review of nanotechnology applications in ovarian cancer.
- Summary of existing and emerging nanoformulations for drug delivery.
- Analysis of nanoparticle-based therapeutic strategies.
Main Results:
- Nanotechnology-based drug delivery systems show potential to overcome limitations of conventional therapies.
- Various nanoparticles have been developed for controlled drug delivery to ovarian cancer.
- Current research focuses on novel nanoparticle strategies to improve treatment efficacy.
Conclusions:
- Nanotechnology holds significant potential for advancing ovarian cancer systemic therapy.
- Further research is needed to address challenges and optimize nanoparticle-based treatments.
- Nanoparticle drug delivery systems offer a promising avenue for precision medicine in ovarian cancer.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
01:27Tumor Immunotherapy